The Clinicopathologic Significance of Inflammasome Activation in Autoimmune Diseases.
Autoimmune diseases are characterized by dysregulated immune tolerance to self and inflammatory damage to tissues and organs. The development of inflammation involves multiple innate and adaptive immune pathways. Inflammasomes are multimeric cytosolic protein complexes that form to mediate host immune responses upon recognizing pathogen- or danger-associated molecular patterns via pattern recognition receptors (PRRs). The accelerating pace of inflammasome research has demonstrated important roles for inflammasome activation in many pathologic conditions encompassing infectious, metabolic, autoinflammatory, and autoimmune diseases. The inflammasome is generally comprised of a PRR, pro-caspase-1 and an adaptor molecule connecting the PRR and pro-caspase-1. With inflammasome activation, pro-caspase-1 becomes active caspase-1 that converts pro-IL-1β and pro-IL-18 into mature and active IL-1β and IL-18, respectively. Having multipotent effects on immune and non-immune cells, the cytokines IL-1β and IL-18 induce and promote systemic and local inflammatory responses. Human studies have reported increased levels of these cytokines, altered activation of inflammasome-related molecules, and/or presence of inflammasome activators in rheumatic diseases including systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), crystal-induced arthropathies, and Sjögren's syndrome. Such changes are found in the primary target organs like the kidneys, joints and salivary glands as well as in the cardiovascular system. In animal models of rheumatic diseases, inflammation and tissue damage improves upon genetic or pharmacologic targeting of the inflammasome, supporting its pathogenic role. Here, we review the clinicopathologic significance and therapeutic targeting of inflammasome activation in rheumatic diseases and related conditions based on recent findings.